Lupin Reports Mixed Q2 Results with Revenue Growth and Margin Pressure

Consolidated Revenue: Rs 7,827.26 crore (up 11.1% YoY)
Net Profit After Tax: Rs 1,155.3 crore (down 22.2% YoY)

Reader Takeaway: Revenue growth remains healthy, but profitability is under pressure due to antitrust settlement costs and acquisition integration.

What just happened

Lupin posted a double-digit revenue increase in the second quarter of FY27, reaching Rs 7,827.26 crore. Despite this top-line performance, consolidated net profit slid to Rs 1,155.3 crore. The company’s standalone results notably swung to a net loss of Rs 5.91 crore, contrasting sharply with the Rs 1,357.35 crore profit recorded in the same period last year.

Why this matters

The bottom-line decline is significantly impacted by non-operational outflows, primarily a Rs 316.28 crore settlement related to long-standing antitrust litigation. Investors are also digesting the financial impact of aggressive inorganic growth, specifically the Rs 2,090.27 crore acquisition of VISUfarma B.V. and the increased stake in Multicare Pharmaceuticals Philippines Inc.

Risks to watch

Legal headwinds continue to be a concern, as the company manages several civil lawsuits regarding alleged anticompetitive behavior. Furthermore, the integration costs and initial drag from the recent VISUfarma acquisition may continue to impact margins in the coming quarters.

What to track next

Shareholders should monitor the company's ability to normalize margins as the newly acquired assets begin contributing to operational cash flows and as legal expenses stabilize.